Vaccines enters cell and changed the DNA
Mordena - and why they will be successful to launch the vaccine
Mordena
Moderna produced the vaccine in collaboration with the National Institute of Allergy and Infectious Diseases, the institute that is headed by Dr. Anthony Fauci and has been leading the clinical trials. Part of the National Institutes of Health, the agency is involved in research on other experimental coronavirus vaccines. Moderna and Johnson & Johnson have each received roughly half a billion dollars from the U.S. government, to speed development of a vaccine.
Who are the major shareholders of Moderna:
1. IPO in 2018 -
Valuation: $7.5 B
Raised : $604.3 M
Moderna sold about 26.3 million shares priced at $23 a share late Thursday, at the midpoint of the projected range of $22 to $24
2. Today on 2020.05.19
$76.28
1. IPO in 2018 -
Valuation: $7.5 B
Raised : $604.3 M
Moderna sold about 26.3 million shares priced at $23 a share late Thursday, at the midpoint of the projected range of $22 to $24
2. Today on 2020.05.19
$76.28
In January 2016, we entered a global health project framework agreement with the Bill & Melinda Gates Foundation to advance mRNA-based development projects for various infectious diseases. The Bill & Melinda Gates Foundation has committed up to $20.0 million in grant funding to support our initial project related to the evaluation of antibody combinations in a preclinical setting as well as the conduct of a first-in-human Phase 1 clinical trial of a potential mRNA medicine to help prevent human immunodeficiency virus, or HIV, infections. Follow-on projects which could bring total potential funding under the framework agreement up to $100.0 million (including the HIV antibody project) to support the development of additional mRNA-based projects for various infectious diseases can be proposed and approved until the sixth anniversary of the framework agreement, subject to the terms of the framework agreement, including our obligation to grant to the Bill &Melinda Gates Foundation certain non-exclusive licenses.